Amgen's earnings call highlighted a strong Q2 performance, driving upward revisions to full-year guidance.  The partnership with Glaxo Smith Kline for international denosumab commercialization is a significant positive, offsetting some concerns about the impact of competitive threats.  Management expressed confidence in the denosumab pipeline and its potential, suggesting a positive outlook for the next few weeks.
[1]
